PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue34,24021,0789,1994,364
Cost of Revenue9,30215,2318,398730
Gross Profit24,9385,8478013,634
Operating Expenses
Research Development32,54728,05923,60819,025
Selling General and Administrative11,69912,30510,3568,279
Non Recurring----
Others----
Total Operating Expenses53,54855,59542,36228,034
Operating Income or Loss-19,308-34,517-33,163-23,670
Income from Continuing Operations
Total Other Income/Expenses Net-7,149-48,9233,987-3,612
Earnings Before Interest and Taxes-19,308-34,517-33,163-23,670
Interest Expense-154-572-3,364-3,549
Income Before Tax-26,457-83,440-29,176-27,282
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-26,457-83,440-29,176-27,282
Non-recurring Events
Discontinued Operations---18985,319
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-26,457-83,440-29,36558,037
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-26,457-83,440-29,36558,037